We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A pair of pairs

16 March 2005 By Robert Cyran

Shares in the Swiss drug maker s subsidiary are bubbling over. They have risen more than 20% this week on news of a cancer drug s success. Genentech s frothy valuation opens up attractive pair trades involving the group, the parent company and the sector.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)